Research finds insufficient data transparency for FDA-cleared AI devices in Alzheimer’s imaging, raising bias and generalizability concerns.
Key Details
- 124 AI/ML-based devices for Alzheimer's disease and related dementias (ADRD) were FDA-authorized between January 2015 and December 2024.
- 291.7% (22/24) were cleared via the 510(k) pathway; 8.3% (2/24) through de novo classification.
- 3For 12 devices, there was no info on training or validation data in FDA summaries or peer-reviewed articles.
- 4Only 2 FDA summaries (8.3%) included external validation data; 10 peer-reviewed articles (41.7%) provided such data.
- 5Reporting of disease status, age, sex, race, and ethnicity was rare across most devices; demographic transparency was lacking.
- 6Most devices (21) were reviewed by radiology panels and primarily involved MRI and PET imaging.
Why It Matters
Transparent disclosure of training and validation data, especially demographic details, is vital for assessing bias and clinical accuracy in AI-based imaging devices. Without sufficient data transparency, there is uncertainty about the generalizability and safety of these AI tools in real-world, diverse patient populations.
Source
AuntMinnie
Related News
•Radiology Business
Medicare Denies Over Half of Radiology AI Claims, Study Finds
Medicare denied $16 million in radiology AI claims between 2018 and 2023, rejecting over half submitted.
•AuntMinnie
AI Advancements Improve MRI Speed, Quality, and Radiologist Workflows
AI is revolutionizing MRI by reducing wait times, addressing burnout, enhancing cardiac imaging, and eliminating traditional trade-offs between scan speed and image quality.
•AuntMinnie
Medicare Covers Half of Radiology SaaS AI Claims, Study Finds
Medicare reimbursed only about 47% of radiology SaaS AI claims between 2018 and 2023, denying over $16 million in payments.